• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

序列定义的杂多价精确定向糖巨肽,带有磺酸化/硫酸化非糖基部分,优先结合半乳糖凝集素-3,并在体外划痕实验中延迟半乳糖凝集素-3 阳性肿瘤细胞系的伤口愈合。

Sequence-Defined Heteromultivalent Precision Glycomacromolecules Bearing Sulfonated/Sulfated Nonglycosidic Moieties Preferentially Bind Galectin-3 and Delay Wound Healing of a Galectin-3 Positive Tumor Cell Line in an In Vitro Wound Scratch Assay.

机构信息

Institute of Organic and Macromolecular Chemistry, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, Düsseldorf, 40225, Germany.

Laboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstr. 20, Aachen, 52074, Germany.

出版信息

Macromol Biosci. 2020 Sep;20(9):e2000163. doi: 10.1002/mabi.202000163. Epub 2020 Jul 26.

DOI:10.1002/mabi.202000163
PMID:32715650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9831253/
Abstract

Within this work, a new class of sequence-defined heteromultivalent glycomacromolecules bearing lactose residues and nonglycosidic motifs for probing glycoconjugate recognition in carbohydrate recognition domain (CRD) of galectin-3 is presented. Galectins, a family of β-galactoside-binding proteins, are known to play crucial roles in different signaling pathways involved in tumor biology. Thus, research has focused on the design and synthesis of galectin-targeting ligands for use as diagnostic markers or potential therapeutics. Heteromultivalent precision glycomacromolecules have the potential to serve as ligands for galectins. In this work, multivalency and the introduction of nonglycosidic motifs bearing either neutral, amine, or sulfonated/sulfated groups are used to better understand binding in the galectin-3 CRD. Enzyme-linked immunosorbent assays and surface plasmon resonance studies are performed, revealing a positive impact of the sulfonated/sulfated nonglycosidic motifs on galectin-3 binding but not on galectin-1 binding. Selected compounds are then tested with galectin-3 positive MCF 7 breast cancer cells using an in vitro would scratch assay. Preliminary results demonstrate a differential biological effect on MCF 7 cells with high galectin-3 expression in comparison to an HEK 293 control with low galectin-3 expression, indicating the potential for sulfonated/sulfated heteromultivalent glycomacromolecules to serve as preferential ligands for galectin-3 targeting.

摘要

在这项工作中,我们提出了一类新的序列定义的杂合多价糖基大分子,它们带有乳糖残基和非糖基结构域,用于探测半乳糖凝集素-3(Galectin-3)中糖缀合物识别的碳水化合物识别结构域(CRD)。半乳糖凝集素是一类β-半乳糖苷结合蛋白,已知在涉及肿瘤生物学的不同信号通路中发挥关键作用。因此,研究集中在设计和合成针对半乳糖凝集素的靶向配体,用作诊断标志物或潜在的治疗药物。杂合多价精确糖基大分子有可能作为半乳糖凝集素的配体。在这项工作中,我们使用多价性和引入带有中性、胺基或磺化/硫酸化基团的非糖基结构域来更好地理解半乳糖凝集素-3 CRD 中的结合。进行了酶联免疫吸附测定和表面等离子体共振研究,结果表明磺化/硫酸化非糖基结构域对半乳糖凝集素-3 的结合有积极影响,但对半乳糖凝集素-1 的结合没有影响。然后,用半乳糖凝集素-3 阳性 MCF 7 乳腺癌细胞和体外划痕试验对选定的化合物进行测试。初步结果表明,与低半乳糖凝集素-3 表达的 HEK 293 对照相比,高半乳糖凝集素-3 表达的 MCF 7 细胞具有不同的生物学效应,表明磺化/硫酸化杂合多价糖基大分子有可能作为半乳糖凝集素-3 靶向的优先配体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/8d959694b187/nihms-1859982-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/ff94378ad8f7/nihms-1859982-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/07bf60717463/nihms-1859982-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/a6f4cf8cdc18/nihms-1859982-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/8d959694b187/nihms-1859982-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/ff94378ad8f7/nihms-1859982-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/07bf60717463/nihms-1859982-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/a6f4cf8cdc18/nihms-1859982-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e01/9831253/8d959694b187/nihms-1859982-f0004.jpg

相似文献

1
Sequence-Defined Heteromultivalent Precision Glycomacromolecules Bearing Sulfonated/Sulfated Nonglycosidic Moieties Preferentially Bind Galectin-3 and Delay Wound Healing of a Galectin-3 Positive Tumor Cell Line in an In Vitro Wound Scratch Assay.序列定义的杂多价精确定向糖巨肽,带有磺酸化/硫酸化非糖基部分,优先结合半乳糖凝集素-3,并在体外划痕实验中延迟半乳糖凝集素-3 阳性肿瘤细胞系的伤口愈合。
Macromol Biosci. 2020 Sep;20(9):e2000163. doi: 10.1002/mabi.202000163. Epub 2020 Jul 26.
2
Glycodendrimers and Modified ELISAs: Tools to Elucidate Multivalent Interactions of Galectins 1 and 3.糖树状大分子与改良酶联免疫吸附测定法:阐明半乳糖凝集素1和3多价相互作用的工具
Molecules. 2015 Apr 20;20(4):7059-96. doi: 10.3390/molecules20047059.
3
Evaluating the affinity and kinetics of small molecule glycomimetics for human and mouse galectin-3 using surface plasmon resonance.使用表面等离子体共振技术评估小分子糖模拟物对人和小鼠半乳糖凝集素-3的亲和力和动力学。
SLAS Discov. 2023 Jul;28(5):233-239. doi: 10.1016/j.slasd.2023.03.005. Epub 2023 Mar 28.
4
Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity.半乳糖凝集素-1和-3及其配体在肿瘤生物学中的作用。不同肿瘤细胞系在细胞表面呈现以及对基质糖蛋白黏附的调节方面具有非均匀特性,在游离型和脂质体结合型半乳糖凝集素的生物分布以及有无转移倾向的乳腺癌和结直肠癌中的表达方面也存在非均匀特性。
J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):461-74. doi: 10.1007/s004320050303.
5
The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific glycosphingolipids with high affinity.半乳糖凝集素-8的N端碳水化合物识别结构域以高亲和力识别特定的糖鞘脂。
Glycobiology. 2003 Oct;13(10):713-23. doi: 10.1093/glycob/cwg094. Epub 2003 Jul 8.
6
Galectin-loaded cells as a platform for the profiling of lectin specificity by fluorescent neoglycoconjugates: a case study on galectins-1 and -3 and the impact of assay setting.载有半乳糖凝集素的细胞作为通过荧光新糖缀合物分析凝集素特异性的平台:以半乳糖凝集素-1和-3为例及分析设置的影响
Glycobiology. 2008 Apr;18(4):315-24. doi: 10.1093/glycob/cwn009. Epub 2008 Feb 6.
7
Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition.小家鼠半乳糖凝集素-9 N端碳水化合物识别结构域的晶体结构揭示了碳水化合物识别的基本机制。
J Biol Chem. 2006 Nov 24;281(47):35884-93. doi: 10.1074/jbc.M606648200. Epub 2006 Sep 21.
8
CUREs for high-level Galectin-3 expression.高表达半乳糖凝集素-3的治疗方法。
Protein Expr Purif. 2024 Sep;221:106516. doi: 10.1016/j.pep.2024.106516. Epub 2024 May 25.
9
Metazoan Soluble β-Galactoside-Binding Lectins, Galectins: Methods for Purification, Characterization of Their Carbohydrate-Binding Specificity, and Probing Their Ligands.后生动物可溶性β-半乳糖苷结合凝集素,半乳糖凝集素:糖结合特异性的纯化、表征方法及其配体的探测。
Methods Mol Biol. 2020;2132:39-54. doi: 10.1007/978-1-0716-0430-4_5.
10
Complex N-glycans are the major ligands for galectin-1, -3, and -8 on Chinese hamster ovary cells.复杂N-聚糖是中国仓鼠卵巢细胞上半乳糖凝集素-1、-3和-8的主要配体。
Glycobiology. 2006 Apr;16(4):305-17. doi: 10.1093/glycob/cwj063. Epub 2005 Nov 29.

引用本文的文献

1
Molecular Recognition of Glycan-Bearing Glycomacromolecules Presented at Membrane Surfaces by Lectins: An NMR View.凝集素对膜表面呈现的含糖聚糖大分子的分子识别:核磁共振视角
ACS Omega. 2023 May 3;8(19):16883-16895. doi: 10.1021/acsomega.3c00634. eCollection 2023 May 16.
2
Network Pharmacology, Molecular Docking, and Experimental Validation to Unveil the Molecular Targets and Mechanisms of Compound Fuling Granule to Treat Ovarian Cancer.网络药理学、分子对接及实验验证揭示复方茯苓颗粒治疗卵巢癌的作用靶点及机制
Oxid Med Cell Longev. 2022 Aug 23;2022:2896049. doi: 10.1155/2022/2896049. eCollection 2022.
3
The Complex Biological Effects of Pectin: Galectin-3 Targeting as Potential Human Health Improvement?

本文引用的文献

1
High-Affinity -(2-Hydroxypropyl)methacrylamide Copolymers with Tailored -Acetyllactosamine Presentation Discriminate between Galectins.高亲和性-(2-羟丙基)甲基丙烯酰胺共聚物,具有定制的乙酰乳糖胺呈现,可区分半乳糖凝集素。
Biomacromolecules. 2020 Feb 10;21(2):641-652. doi: 10.1021/acs.biomac.9b01370. Epub 2020 Jan 23.
2
Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure.与肝素衍生结合抑制剂的相互作用会破坏半乳糖凝集素-3 蛋白结构。
Biochem Biophys Res Commun. 2020 Mar 5;523(2):336-341. doi: 10.1016/j.bbrc.2019.12.054. Epub 2019 Dec 19.
3
: F-Radiolabeled Glycomimetics Allow Insights into the Pharmacological Fate of Galectin-3 Inhibitors.
果胶的复杂生物学效应:半乳凝集素-3靶向作为潜在的人类健康改善?
Biomolecules. 2022 Feb 10;12(2):289. doi: 10.3390/biom12020289.
4
Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?用α-乳糖调节Gal-9/TIM-3免疫检查点。乳糖的异头物重要吗?
Cancers (Basel). 2021 Dec 18;13(24):6365. doi: 10.3390/cancers13246365.
F-放射性标记的糖模拟物可深入了解半乳糖凝集素-3 抑制剂的药理命运。
J Med Chem. 2020 Jan 23;63(2):747-755. doi: 10.1021/acs.jmedchem.9b01692. Epub 2020 Jan 3.
4
3-Substituted 1-Naphthamidomethyl-C-galactosyls Interact with Two Unique Sub-sites for High-Affinity and High-Selectivity Inhibition of Galectin-3.3-取代 1-萘甲酰胺基-C-半乳糖基与两个独特的亚结合位点相互作用,对半乳糖凝集素-3 具有高亲和力和高选择性抑制作用。
Molecules. 2019 Dec 12;24(24):4554. doi: 10.3390/molecules24244554.
5
Roles of galectin-3 in metabolic disorders and tumor cell metabolism.半乳糖凝集素-3 在代谢紊乱和肿瘤细胞代谢中的作用。
Int J Biol Macromol. 2020 Jan 1;142:463-473. doi: 10.1016/j.ijbiomac.2019.09.118. Epub 2019 Oct 8.
6
Selective and Tunable Galectin Binding of Glycopolymers Synthesized by a Generalizable Conjugation Method.通过一种可推广的偶联方法合成的糖聚合物的半乳糖凝集素的选择性和可调性结合。
Biomacromolecules. 2019 Oct 14;20(10):3704-3712. doi: 10.1021/acs.biomac.9b00759. Epub 2019 Sep 6.
7
Aminopyrimidine-galactose hybrids are highly selective galectin-3 inhibitors.氨基嘧啶-半乳糖杂合物是高度选择性的半乳糖凝集素-3抑制剂。
Medchemcomm. 2019 May 13;10(6):913-925. doi: 10.1039/c9md00183b. eCollection 2019 Jun 1.
8
Extracellular and intracellular small-molecule galectin-3 inhibitors.细胞外和细胞内小分子半乳糖凝集素-3 抑制剂。
Sci Rep. 2019 Feb 18;9(1):2186. doi: 10.1038/s41598-019-38497-8.
9
Design-functionality relationships for adhesion/growth-regulatory galectins.粘附/生长调节半乳糖凝集素的设计功能关系。
Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2837-2842. doi: 10.1073/pnas.1813515116. Epub 2019 Feb 4.
10
Double-Modified Glycopolymers from Thiolactones to Modulate Lectin Selectivity and Affinity.用于调节凝集素选择性和亲和力的由硫内酯制备的双修饰糖聚合物
ACS Macro Lett. 2018 Dec 18;7(12):1498-1502. doi: 10.1021/acsmacrolett.8b00825. Epub 2018 Dec 6.